Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Antibody-mediated Rejection: early-phase trial registry
4 of 6 indexed Antibody-mediated Rejection trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,866 of 28,707 conditions by registered trial count.
6 US clinical trials · 4 currently recruiting · #2,866 of 28,707 conditions by registered trial count
Antibody-mediated Rejection: 6 US clinical trials tracked, 4 recruiting.
Antibody-mediated Rejection is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Stanley Jordan, MD, running 1 of these trials.
Enrollment posture brief
Registry condition antibody-mediated-rejection
OPEN 4 | RECR 67% | LATE 1 | EARLY 3 | RANK #2866 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Adenocarcinoma of Lung (67% recruiting · 6 trials)
Antibody-mediated Rejection lists 4 open slots (67% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Antibody-mediated Rejection on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Antibody-mediated Rejection is recruiting above its size-band peers.
4 of 6 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Antibody-mediated Rejection research.
Stanley Jordan, MD accounts for 1 of 6 trials (16.7%). 6 distinct sponsors appear on at least one study for this condition label.
-
Typical Antibody-mediated Rejection enrolment sits around 120 participants.
Median target enrolment is 120 among the 6 trials that report a genuine target (sentinel values excluded). 3 of those (50%) plan for fewer than 100 participants.
-
Antibody-mediated Rejection splits between interventional and observational designs.
4 interventional and 2 observational studies make up this index (66.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
6 total, page 1 of 1
Biorepository and Registry for Plasma Exchange Patients
Charles M Knudson
NCT05004493
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)
Biogen
NCT06685757
Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
Alexion Pharmaceuticals
NCT06744647
A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)
argenx
NCT06503731
VIRTUUS Children's Study
Children's Hospital of Philadelphia
NCT03719339
Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant
Stanley Jordan, MD
NCT03380962
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Antibody-mediated Rejection records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Antibody-mediated Rejection trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Antibody-mediated Rejection page
6 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Antibody-mediated Rejection trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Stanley Jordan, MD sponsors the most Antibody-mediated Rejection trials on record, review their full trial history before evaluating a specific study. See Stanley Jordan, MD's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Antibody-mediated Rejection condition card totals 6 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.